
GITNUXSOFTWARE ADVICE
EconomicsTop 10 Best Health Economics Services of 2026
Compare health economics services with clear tradeoffs and fit for healthcare teams, using market research examples from Milliman and peers.
How we ranked these tools
Vendors set the topic, but our editors set the inclusion criteria and the evaluation framework before research starts.
Agents extract product evidence with provenance, then collect written reviews and transcribe video reviews and podcasts.
Framework: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page — this does not influence rankings. Editorial policy
Milliman is the best choice for payer and sponsor teams needing rigorous, consultant-built economic models because it gives end-to-end control of assumptions from evidence inputs through decision-ready framing, while L.E.K. Consulting fits when reimbursement stakeholders need repeatable, traceable scenario reruns.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
Milliman
End-to-end control of economic model assumptions from evidence inputs through results framing for decision committees.
Best for: Fits when payer and sponsor teams need rigorous, consultant-built economic models with decision-ready documentation.
L.E.K. Consulting
Editor pickEnd-to-end economic modeling and evidence-to-outputs traceability that supports repeatable scenario reruns for policy decisions.
Best for: Fits when reimbursement and payer stakeholders need defensible economic modeling, sensitivity logic, and traceable assumptions.
Simon-Kucher & Partners
Editor pickDecision narrative integration that connects model assumptions and scenario results to commercial and HTA-facing positions.
Best for: Fits when teams need decision-ready health economics tied to pricing and reimbursement negotiation.
Comparison Table
Milliman
specialistActuarial and healthcare consulting firm offering health economics and policy analysis.
End-to-end control of economic model assumptions from evidence inputs through results framing for decision committees.
Milliman typically delivers custom economic models built around specified decision contexts, such as reimbursement strategy, formulary evidence, and portfolio-level prioritization. Its engagement patterns favor technical continuity through modeling and write-up phases, which reduces rework when stakeholders request changes to assumptions, endpoints, or comparator structures. The work often extends beyond deterministic outputs into uncertainty handling that supports scenario analysis for decision meetings.
A tradeoff appears when stakeholders expect an off-the-shelf modeling system or rapid self-service configuration, since Milliman’s value concentrates in analyst-run studies rather than productized automation. Milliman fits best when internal teams need an external modeling partner to translate clinical and utilization evidence into decision-ready outputs for governance and health technology assessment committees.
- +Analyst ownership across modeling, assumptions, and decision narrative
- +Strong support for comparator, horizon, and perspective changes
- +Clear traceability from evidence inputs to model outputs
- +Consistent handling of uncertainty for scenario-based discussions
- –Limited self-service experience compared with workflow tools
- –Requires disciplined scoping to avoid repeated assumption revisions
- –Turnaround depends on data availability and stakeholder feedback cadence
- –Advanced model customization can increase project complexity
Payer medical policy teams
Budget impact for new therapy
Governance-ready reimbursement recommendation
HTA and reimbursement analysts
Cost-effectiveness dossier support
Defensible ICER estimates
Show 2 more scenarios
Life sciences market access
Scenario analysis for launch planning
Improved decision alignment
Assumption and endpoint variants support internal tradeoffs for market access strategy.
Clinical evidence and HEOR leads
Evidence-to-model integration
Faster stakeholder review
Model inputs are connected to clinical endpoints and resource utilization assumptions.
Best for: Fits when payer and sponsor teams need rigorous, consultant-built economic models with decision-ready documentation.
L.E.K. Consulting
enterprise_vendorStrategy consulting firm with life sciences practice including health economics services.
End-to-end economic modeling and evidence-to-outputs traceability that supports repeatable scenario reruns for policy decisions.
Health economics work at L.E.K. typically centers on building and populating economic models that connect treatment effects, healthcare resource utilization, and cost inputs into decision-ready results. The engagement style fits teams that need controlled assumptions, documented sensitivity logic, and results that can be defended in cross-functional review cycles. Automation is most useful when internal users require consistent reruns for scenario analysis and policy variants rather than one-off model builds. Integration depth tends to be strongest when stakeholders align on model specifications early and provide the evidence inputs needed for build and QA cycles.
A key tradeoff is that deep economic-model custom work benefits from early requirements clarity, because model structure choices and evidence mapping drive downstream build effort. L.E.K. works best when timelines require disciplined iteration on discounting, perspective, time horizon, and sensitivity parameters, such as probabilistic sensitivity analysis and scenario analysis for HTA-style submissions. For usage situations where internal teams already have a preferred modeling template, L.E.K. can integrate more smoothly by aligning to the existing structure and reporting conventions. For teams seeking only lightweight scoping or presentation, the consulting approach can feel heavier than model-only support.
Governance and auditability tend to be handled through structured workplans, explicit assumption logs, and controlled output formats that support internal and external review. This fits payer-facing and reimbursement workflows where decision makers need traceable rationale from evidence to incremental outcomes. It also fits multi-stakeholder programs where clinical, economic, and policy teams must converge on the same parameter definitions.
- +Decision-grade economic outputs linked to explicit assumptions
- +Scenario analysis support for payer policy and reimbursement use
- +Structured sensitivity work suitable for HTA-style scrutiny
- +Clear traceability from evidence inputs to incremental results
- –Requires early alignment on model structure and evidence mapping
- –Heavier consulting footprint than model-only support
- –API and automation options are not a self-serve modeling product
- –Rerun throughput depends on how inputs and drivers are packaged
Payer health economics teams
HTA-style cost-effectiveness scenario modeling
Defensible reimbursement narrative
Market access strategy teams
Policy variant and sensitivity reruns
Consistent decision outputs
Show 2 more scenarios
Biopharma HEOR leads
Evidence synthesis to economic model inputs
Faster model readiness
Maps evidence findings into model parameters with controlled assumptions and documented sensitivities.
Clinical trial economics leads
Resource use and cost parameter translation
Aligned economic assumptions
Converts healthcare utilization evidence into cost inputs to produce decision-grade economic results.
Best for: Fits when reimbursement and payer stakeholders need defensible economic modeling, sensitivity logic, and traceable assumptions.
Simon-Kucher & Partners
enterprise_vendorGlobal strategy consulting firm with pharmaceutical pricing and health economics practice.
Decision narrative integration that connects model assumptions and scenario results to commercial and HTA-facing positions.
Simon-Kucher & Partners supports health economics studies that connect clinical evidence to economic decision criteria, including model-based assessments and comparative scenarios. Delivery commonly targets decision artifacts such as cost drivers, assumptions documentation, and justification packages for stakeholders who need to align technical results with commercial positions.
A tradeoff appears when internal teams need heavy hands-on model building guidance, because engagement leadership typically focuses on deliverables rather than extensive knowledge transfer to every model component. Simon-Kucher & Partners fits best when a payer or pharma team needs an economics partner to manage end-to-end reasoning from evidence inputs to decision narrative, then stress assumptions for distinct negotiating or reimbursement scenarios.
- +Strong linkage between economic outputs and commercial decision framing
- +Clear assumption documentation for stakeholder review and alignment
- +Scenario work that supports pricing and reimbursement argumentation
- +Experience running economic models suitable for HTA-style questions
- –Less hands-on model coaching for teams building from scratch
- –Model scope can widen when evidence gaps require extra synthesis
- –Governance artifacts may be time-consuming for fast-moving teams
- –Interaction bandwidth can be limiting for highly iterative cycles
Pricing and market access teams
Prepare reimbursement negotiation economic evidence
Aligned decision package for stakeholders
HTA strategy leads
Respond to assessment questions
Clearer internal HTA response
Show 2 more scenarios
RWE and evidence teams
Quantify economic model parameters
Model inputs grounded in evidence
Use evidence synthesis to populate cost and utilization inputs for comparative analyses.
Portfolio decision groups
Compare strategic investment options
Comparable options for selection
Support comparative evaluations using consistent assumptions across scenarios for decision makers.
Best for: Fits when teams need decision-ready health economics tied to pricing and reimbursement negotiation.
IQVIA
enterprise_vendorGlobal healthcare data, analytics, and research organization with health economics services.
A structured model-assembly workflow that traces evidence inputs into parameter definitions and reporting deliverables for submission-style review.
IQVIA delivers health economics services that connect evidence synthesis, model building, and decision-ready outputs for payer and provider stakeholders. Teams commonly support economic model development across decision tree, Markov, and partitioned survival structures, with transparent assumptions for time horizon, perspective, and discounting.
- +End-to-end workflow from evidence inputs to calibrated economic model outputs
- +Strong support for multiple model structures used in reimbursement submissions
- +Documented assumption management for time horizon, perspective, and discounting
- +Data-to-parameter mapping from claims or EHR into resource and outcomes inputs
- –Governance-heavy delivery can slow timelines for narrow-scope requests
- –Complex modeling work increases dependency on timely client data provisioning
- –Less suitable for teams needing fully self-serve model authoring
- –Requires clear alignment on endpoints and utility inputs early in planning
Best for: Fits when payer-facing economic models need rigorous evidence linkage and controlled, reviewable assumptions.
ICON plc
enterprise_vendorClinical research organization providing health economics and outcomes research services.
Project-managed economic model builds with documented assumption traceability across scenarios and sensitivity workstreams.
ICON plc produces health economics and outcomes research deliverables, including full economic model builds and analyses for health technology assessment and payer decisions. Teams support decision-ready outputs that connect clinical evidence inputs to cost and utility assumptions, with documented model logic used across scenario and sensitivity work.
- +End-to-end ownership of economic modeling from evidence inputs to submission outputs
- +Clear traceability from assumptions to drivers in scenario and sensitivity results
- +Experience translating clinical endpoints into utility and cost parameters for decision use
- +Structured project management for coordinated model, reporting, and response cycles
- –Collaboration depends on timely provision of evidence packages and cost frameworks
- –Less suited for teams needing self-serve model tooling and analyst workflows
- –Model customization depth may increase iteration cycles during scoping changes
- –Output polish is strong for submissions but limited for rapid internal experimentation
Best for: Fits when sponsors need managed health economics modeling and submission-grade decision outputs.
Costello Medical
specialistHealth economics and medical communications consultancy serving global life sciences clients.
Senior-led decision modeling that ties evidence inputs to transparent assumptions and stakeholder-ready scenario interpretation.
Costello Medical is a health economics and health technology assessment consultancy built for teams that need defensible economic modeling for submissions and payer negotiations. Core work covers evidence synthesis to populate economic models, alongside model development for typical decision-analytic structures and uncertainty work that supports stakeholder decision-making.
- +Consultancy-led modeling with strong assumption traceability for submission scrutiny
- +Clear linkage between evidence inputs and model parameters for governance-ready reviews
- +Experienced handling of uncertainty work for payer-focused decision narratives
- +Practical scenario design aligned to access and policy questions
- –Delivery depends on consultancy resourcing rather than self-serve workflows
- –Heavier governance documentation can increase internal review time for new teams
- –Model handover format may require analyst support to re-run and audit fully
Best for: Fits when payer-facing economic models must align evidence, assumptions, and uncertainty for HTA timelines.
Charles River Associates
specialistEconomics and finance consulting firm with healthcare and life sciences practice.
Policy-focused modeling documentation that ties evidence inputs to economic assumptions and scenario outcomes for technical scrutiny.
Charles River Associates delivers health economics work rooted in applied decision modeling and policy-grade economic analysis, often executed for complex payer, regulator, and litigation timelines. Core capabilities include comparative economic evaluations, budget impact analysis, and evidence-informed model building that supports reimbursement and HTA-style decision framing.
- +Strong capability for decision-analytic modeling across multi-stage pathways
- +Costing assumptions are built to withstand regulator and payer scrutiny
- +Transparent scenario logic supports line-by-line technical review
- +Experienced at evidence synthesis inputs for model-based economic outcomes
- –Collaboration requires tight technical scoping to avoid rework
- –Automation and API surface are limited since delivery is largely services-based
- –Turnaround depends on model scope and evidence procurement complexity
- –Governance controls are more consultative than software-native
Best for: Fits when policy-grade economic models need strong documentation and defensible scenario framing for reimbursement or regulatory review.
Putnam Associates
specialistStrategy consulting firm serving life sciences with health economics and value evidence services.
Engagement-led economic modeling that prioritizes dossier-ready transparency of assumptions, scenarios, and results.
Putnam Associates delivers health economics services built around economic modeling, value evidence, and decision support for payers and life sciences. Teams commonly use its modeling work for payer-facing health technology assessment and comparative effectiveness decisions that need transparent assumptions and repeatable calculations.
- +End-to-end economic model development for stakeholder-ready deliverables
- +Consistent handling of model assumptions and scenario structures across engagements
- +Experience supporting payer and HTA-style economic decision contexts
- +Clear support for decision-oriented reporting needs and impact narratives
- –Collaboration overhead can rise when inputs require heavy data cleaning
- –Model refinement cycles may take longer when endpoints or estimands shift late
- –Tooling depth is limited for users expecting self-serve modeling automation
- –Governance controls depend on engagement process rather than productized workflows
Best for: Fits when stakeholder-facing health economic models must be built, maintained, and documented end to end.
RTI Health Solutions
specialistHealth economics and outcomes research consulting firm serving pharmaceutical and medical device clients.
Decision-focused economic modeling deliverables that translate evidence to scenario-specific incremental results.
RTI Health Solutions produces health economics and outcomes research deliverables that connect clinical evidence to payer and policy decisions, with clear emphasis on model-driven decision support. The core work covers cost-effectiveness and related economic modeling, value frameworks, and evidence synthesis outputs used in health technology assessment and comparative effectiveness contexts.
- +Economic modeling work products suited for payer and HTA decision workflows
- +Strong focus on uncertainty handling for scenario and sensitivity outputs
- +Delivery includes stakeholder-ready tables and documentation for model inputs
- +Methodology depth supports complex study design and evidence synthesis decisions
- –Model build timelines can be sensitive to scoping and data availability
- –Integration and automation tooling is not positioned as an API-first service
- –Customization requests can require higher-level oversight from client leads
- –Outputs remain document-centric rather than interactive for model exploration
Best for: Fits when payers, sponsors, or HTA groups need decision-grade economic modeling with documented assumptions.
Health Advances
specialistHealthcare strategy consulting firm offering health economics and market access services.
Submission-focused model documentation that ties assumptions to scenario outputs for HTA stakeholder review.
Health Advances delivers health economics and health technology assessment work centered on economic modeling, comparative evidence synthesis, and decision-ready outputs for payer and HTA stakeholders. Teams typically use Health Advances when a study requires a full economic model lifecycle from scope and structure through scenario work and documentation.
- +Economic model build support for decision-ready HTA submissions
- +Structured documentation of model assumptions and scenarios
- +Experience translating clinical endpoints into economic inputs
- +Clear analyst deliverables for reviewers and internal stakeholders
- –Limited evidence of API and automation for internal tooling integration
- –Governance controls appear engagement-based rather than platform-based
- –Model transparency depends heavily on analyst documentation quality
- –Throughput for large multicountry bundles may require parallel workstreams
Best for: Fits when teams need consultant-led economic modeling and HTA-ready documentation for a defined submission scope.
Conclusion
After evaluating 10 health economics, Milliman stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
Frequently Asked Questions About Health Economics
Which providers are the best fit for building a decision model from evidence to outputs with tight traceability?
How do service delivery models differ between consultancy-led work and interactive or tooling-based workflows?
What breaks if the client needs frequent model reruns driven by updated evidence, assumptions, or dossier edits?
When does a budget impact analysis need different expertise than a cost-effectiveness analysis?
How should teams prepare claims data or electronic health record data so model inputs stay auditable?
Which providers handle evidence synthesis tightly enough to populate the economic model without manual translation layers?
What security and governance controls should buyers expect around model change control and audit trails?
How do data migration and model format handoffs affect onboarding timelines for new vendors?
Which providers best support scenario logic that maps cleanly to stakeholder governance and documentation expectations?
When should a project include probabilistic sensitivity work rather than relying only on deterministic sensitivity runs?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
How to Choose the Right Health Economics
We see real differences in how well a health economics tool ties study inputs to outcomes and how transparently it shows results across assumptions. Pick based on evidence traceability and scenario support, not just a polished interface.
Evidence traceability for inputs
Why it matters
Evidence traceability for inputs matters when health economics results need to be defended in reviews and audits. If users can’t trace where parameters come from, findings become hard to replicate or explain.
How to check
In a demo, load an example project and click through a parameter to see its source, date, and citation text. Ask whether the tool stores that link inside the project output so you can export a traceable report.
Assumption and scenario controls
Why it matters
Assumption and scenario controls determine whether you can test alternative interpretations without rebuilding work. Health economics teams often need to compare outcomes under the same structure but different assumptions.
How to check
Set two different assumptions (for example, a key effectiveness value or cost input) and confirm you can switch between them without losing prior results. Check whether scenarios keep separate outputs you can label and export.
Uncertainty workflow for sensitivity
Why it matters
An uncertainty workflow for sensitivity matters because health economics conclusions depend on robustness, not single-point estimates. Tools should let analysts show what changes and why.
How to check
Run a sensitivity exercise using the built-in example or upload a small dataset. Confirm you can review which inputs drive variation and export the uncertainty outputs alongside the main results.
Reproducible outputs from saved settings
Why it matters
Reproducible outputs from saved settings matter for peer review and internal sign-off. If re-running produces different numbers, you can’t credibly audit changes.
How to check
Export results, then reload the project and rerun the same analysis using identical settings. Compare key output figures for exact matches (or documentable differences if the tool explains why).
Transparent reporting of assumptions
Why it matters
Transparent reporting of assumptions helps stakeholders understand what the model assumed and what it did not. In health economics, unclear reporting undermines decision usefulness.
How to check
Generate the standard report for an example study and inspect whether it lists assumptions, sources, and outputs in a consistent structure. Ask if you can edit report sections and ensure exported files retain those details.
Red flags
- Inputs can be changed but sources aren’t stored in the project output
- Scenario changes overwrite results instead of keeping labeled alternatives
- Rerunning the same saved settings produces different outputs without explanation
Fit by situation
- If we need audit-ready documentation for parameters and their origins, prioritize evidence traceability for inputs.
- If we expect stakeholders to challenge assumptions during review, prioritize assumption and scenario controls.
- If we must show robustness rather than point estimates, prioritize uncertainty workflow for sensitivity.
Funding and competing interests
This study was co-funded by several of the vendors assessed in it. No single vendor funded it. Funders could propose the market studied.
They had no role in selecting vendors, setting or weighting criteria, analysing data or drawing conclusions, and they received the same factual-accuracy check as every other vendor assessed.
Market definition, inclusion rules and criteria weights were fixed by an editor before research began and did not change afterwards. Editorial process →
- EconomicsTop 10 Best Behavioral Economics Services of 2026
- Science ResearchTop 10 Best Health Industries Research Services of 2026
- Digital Transformation In IndustryTop 10 Best Health Care Technology Services of 2026
- Healthcare MedicineTop 10 Best Health Services Software of 2026
- Data Science AnalyticsTop 10 Best Economics Software of 2026
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
Economics alternatives
See side-by-side comparisons of economics tools and pick the right one for your stack.
Compare economics tools→